Clinical Trials, Phase I as Topic
"Clinical Trials, Phase I as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.
Descriptor ID |
D017321
|
MeSH Number(s) |
E05.318.760.535.200 E05.337.250.200 N05.715.360.775.235.200 N06.850.520.450.535.200
|
Concept/Terms |
Microdosing Trials, Human- Microdosing Trials, Human
- Human Microdosing Trial
- Microdosing Trial, Human
- Trial, Human Microdosing
- Trials, Human Microdosing
- Human Microdosing Trials
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase I as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase I as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase I as Topic" by people in this website by year, and whether "Clinical Trials, Phase I as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1992 | 1 | 4 | 5 | 1993 | 3 | 1 | 4 | 1994 | 1 | 2 | 3 | 1995 | 2 | 3 | 5 | 1996 | 0 | 2 | 2 | 1997 | 2 | 2 | 4 | 1998 | 0 | 2 | 2 | 1999 | 1 | 2 | 3 | 2000 | 1 | 0 | 1 | 2001 | 2 | 2 | 4 | 2002 | 0 | 3 | 3 | 2003 | 3 | 3 | 6 | 2004 | 2 | 3 | 5 | 2005 | 2 | 3 | 5 | 2006 | 3 | 0 | 3 | 2007 | 4 | 2 | 6 | 2008 | 3 | 0 | 3 | 2009 | 1 | 0 | 1 | 2010 | 1 | 3 | 4 | 2011 | 3 | 4 | 7 | 2012 | 2 | 4 | 6 | 2013 | 2 | 3 | 5 | 2014 | 1 | 8 | 9 | 2015 | 4 | 1 | 5 | 2016 | 4 | 2 | 6 | 2017 | 1 | 0 | 1 | 2018 | 1 | 2 | 3 | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials, Phase I as Topic" by people in Profiles.
-
Guo W, Ji Y, Li D. R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials. J Biopharm Stat. 2019; 29(3):411-424.
-
Hlubocky FJ, Sachs GA, Larson ER, Nimeiri HS, Cella D, Wroblewski KE, Ratain MJ, Peppercorn JM, Daugherty CK. Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials? J Clin Oncol. 2018 08 20; 36(24):2483-2491.
-
Hlubocky FJ, Kass NE, Roter D, Larson S, Wroblewski KE, Sugarman J, Daugherty CK. Investigator Disclosure and Advanced Cancer Patient Understanding of Informed Consent and Prognosis in Phase I Clinical Trials. J Oncol Pract. 2018 06; 14(6):e357-e367.
-
Werntz RP, Eggener SE. Novel focal therapy treatment options for prostate cancer. Curr Opin Urol. 2018 03; 28(2):178-183.
-
Guo W, Wang SJ, Yang S, Lynn H, Ji Y. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2. Contemp Clin Trials. 2017 07; 58:23-33.
-
Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1452-1459.
-
Li DH, Whitmore JB, Guo W, Ji Y. Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials. Clin Cancer Res. 2017 Jan 01; 23(1):13-20.
-
Yeh JC, Huang P, Cohen KJ. Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency. J Pediatr Hematol Oncol. 2016 07; 38(5):360-6.
-
Al-Hallaq HA, Chmura S, Salama JK, Winter KA, Robinson CG, Pisansky TM, Borges V, Lowenstein JR, McNulty S, Galvin JM, Followill DS, Timmerman RD, White JR, Xiao Y, Matuszak MM. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. Pract Radiat Oncol. 2016 Nov - Dec; 6(6):e291-e298.
-
Sweis RF, Ratain MJ. Reply to T.A. Yap et al. J Clin Oncol. 2016 07 10; 34(20):2432-3.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|